Typical clinical uses
- Cycle-tracking and fertility apps with sensor input
- At-home fertility and ovulation hardware
- Connected breast pumps with telemetry
- Pelvic-floor therapeutics and biofeedback devices
- Maternal RPM and postpartum monitoring
Cybersecurity for fertility, maternal, and women's health devices.
Connected women's health devices handle uniquely sensitive data and often integrate consumer-grade hardware with clinical claims. We help manufacturers reach FDA cyber expectations without losing the consumer-product feel.
Women's-health devices span cycle-tracking apps, fertility hardware, breast-pump telemetry, and pelvic-floor therapeutics. Reproductive-health data is subject to evolving federal and state privacy laws on top of HIPAA - the architecture has to accommodate the strictest jurisdiction it will operate in.
Typical clinical uses
Key data flows & integrations
Reproductive and pregnancy data require explicit consent flows, minimal retention, and strong access controls.
Devices that started as consumer products often inherit insecure defaults that need to be removed before clearance.
Women's health devices span at-home wearables, fertility and pregnancy monitors, and connected pelvic-floor or contraceptive devices. Most depend on a phone-as-gateway architecture with a cloud back-end holding sensitive health data.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Women's-health products straddle consumer and FDA-regulated categories under unusually high privacy scrutiny. The relevant history is concentrated on FTC actions for sensitive-data sharing and on cloud-app PHI exposures.
Historical incidents
FTC alleged that Flo's period- and fertility-tracking app shared sensitive health data with third-party analytics SDKs (including Facebook and Google) despite privacy promises. Settlement required independent privacy audits and notice obligations.
FTC, In re Flo Health, Inc., Jan 2021
FTC action against Easy Healthcare (operator of Premom) addressed sharing of fertility-tracking data with third parties - directly relevant to any connected fertility or reproductive-health product, regardless of FDA status.
FTC, In re Easy Healthcare Corp., May 2023
Since 2022, multiple state laws and HHS rulemaking have raised the bar for reproductive-health data handling. Reviewers and notified bodies now expect this addressed in the device's privacy and cybersecurity architecture.
HHS HIPAA Privacy Rule final rule for reproductive health, 2024
Active threat scenarios
Analytics, attribution, or A/B SDKs in a regulated-build of a women's-health app routinely transmit PHI to third parties unless explicitly stripped.
Sharing features without explicit authorization boundaries are a frequent BOLA finding.
Account takeover exposes uniquely sensitive data with elevated legal and reputational risk.
Cloud architectures that move reproductive-health data across borders without explicit handling raise both legal and review concerns.
What FDA reviewers cite
Women's-health devices span cycle-tracking apps, fertility hardware, breast-pump telemetry, and pelvic-floor therapeutics - a sector under heightened privacy scrutiny.
Reproductive-health data is subject to evolving federal and state privacy laws on top of HIPAA - your architecture needs to accommodate the strictest.
Many products straddle wellness and FDA-regulated categories - cyber documentation must be ready when you cross the line.
Analytics, ads, and A/B SDKs are common in consumer-grade apps and a frequent path to PHI leakage - they must be inventoried and controlled.
What FDA scrutinizes
Reproductive-health data is subject to evolving federal and state privacy laws on top of HIPAA - architecture needs to accommodate the strictest.
Many products straddle wellness and FDA-regulated categories - cyber documentation must be ready when you cross the line.
Analytics, ads, and A/B SDKs are common in consumer-grade apps and a frequent path to PHI leakage - they must be inventoried and controlled.
Standards & deliverables
Six deliverables FDA and notified bodies expect across MedTech, with the women's health-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
Signed firmware/software updates with rollback protection, integrity verification, and staged rollout.
Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
Reproductive, menstrual, and fertility data is high-sensitivity health information that can carry legal exposure beyond HIPAA - particularly under state-level reproductive privacy statutes. We model misuse and over-collection alongside conventional confidentiality, integrity, and availability threats, and we recommend explicit retention windows, minimization, and access patterns FDA reviewers and privacy counsel both expect to see. The SPDF documents the data classification, lawful basis, and the controls (encryption, access scoping, audit) that enforce it.
Consumer hardware moving into a regulated indication usually carries baseline hygiene problems - default credentials, exposed debug interfaces (UART/JTAG/SWD), insecure radios, undocumented OTA paths, and unsigned firmware. We run a hardening sweep first, lock down those baseline issues, generate a clean SBOM, and only then build the FDA-aligned premarket cyber package on top. Trying to add the FDA package without remediating the consumer-era debt almost always produces deficiency letters.
Yes. Connected fetal and maternal monitors are networked medical devices with safety-relevant alarms - exactly the class of product the 2026 FDA premarket cyber guidance and AAMI SW96 are written for. Deliverables include the threat model, SBOM (SPDX or CycloneDX) with VEX, security architecture views, authenticated penetration testing of device, app, and cloud, MDS2, labeling content, and a postmarket cybersecurity management plan under section §524B.
Account sharing is modeled as an explicit authorization boundary with explicit consent and revocation flows, not as a UI feature. The API is tested for BOLA (broken object-level authorization), tenancy leaks across linked accounts, and stale-token access after revocation - these are the most common findings in this segment. The threat model and the privacy policy must agree on what a 'partner' can see and for how long; if they don't, the inconsistency surfaces in both FDA review and state AG inquiries.
No. HIPAA covers a slice (covered entities, business associates, breach response) and applies only when the platform is acting in those roles. FDA premarket cybersecurity content is required when the product is a regulated device, regardless of HIPAA status. State-level reproductive privacy laws (e.g., Washington's MHMDA, California, Connecticut) impose additional obligations on consent, sale, and disclosure of reproductive health data and need to be reflected in the security and privacy design.
The SPDF and the privacy notice should tell the same story: storage regions, key custody, replication scope, sub-processor list, and any cross-border transfer mechanisms. We document the data flows in the threat model, identify any data that leaves the primary region (including incidentally - logs, metrics, support tooling), and verify the controls in pen testing. This single coherent story is what reviewers, hospital procurement, and privacy counsel all need.
When predictions affect clinical decisions (e.g., fertility windows used for conception or contraception), the algorithm is part of the regulated software and the cyber package must address its supply chain, model integrity, training data lineage, and adversarial-input resistance. We treat it the same way we treat AI/SaMD: signing, version pinning, load-time verification, and PCCP-aware change control.
Pregnancy data carries an extra duty because it implicates the fetus and, after birth, a separate pediatric record. We document retention separately for the gestational period, postpartum, and pediatric continuation, with explicit deletion paths and parental consent flows. These controls are tested in the cloud pen test and called out in the labeling and IFU.
Yes. Paired wearables (BLE thermometers, smart rings, breast pumps, pelvic-floor trainers) are scoped as part of the system: BLE pairing mode, OTA signing, sensor-spoofing resistance, and battery/DoS handling are all in the test plan. Findings against the wearable feed back into the device-level threat model and SBOM.
Continuous SBOM monitoring across mobile, web, backend, and any wearable firmware; a published Coordinated Vulnerability Disclosure (CVD) intake; defined SLAs by severity; and a documented path from CVE to controlled software change under your QMS. Because this segment frequently ships fast through app stores, the postmarket plan must explicitly address how mobile updates are managed without breaking the cleared interoperability or claims.
Typical end-to-end timeline is 4-8 weeks for a software-only DTx-style product and 8-12 weeks when paired wearables, fetal/maternal monitors, or significant cloud architecture are in scope. Threat modeling and SBOM front-load in weeks 1-3, mobile/web/API and (where applicable) device pen testing run in weeks 3-8, and the consolidated submission package and postmarket plan close out in the final weeks. Scope and clearance-commitment terms are confirmed in writing before kickoff.
Mobile, wearable, and cloud testing for fertility, maternal, and pelvic-health devices.
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
Cybersecurity for fertility, maternal, and women's health devices.
